Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0R7OD
|
||||
| Former ID |
DIB020987
|
||||
| Drug Name |
SRIF-14
|
||||
| Synonyms |
SST-14; somatostatin-14; SS14
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [539297] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C63H88N16O16S2
|
||||
| InChI |
InChI=1S/C63H88N16O16S2/c1-34(66)53(84)69-30-51(83)70-48-32-96-97-33-49(63(94)95)78-60(91)47(31-80)77-62(93)52(35(2)81)79-55(86)42(22-12-14-24-65)71-58(89)45(27-38-29-68-40-20-10-9-19-39(38)40)75-57(88)44(26-37-17-7-4-8-18-37)73-56(87)43(25-36-15-5-3-6-16-36)74-59(90)46(28-50(67)82)76-54(85)41(72-61(48)92)21-11-13-23-64/h3-10,15-20,29,34-35,41-49,52,68,80-81H,11-14,21-28,30-33,64-66H2,1-2H3,(H2,67,82)(H,69,84)(H,70,83)(H,71,89)(H,72,92)(H,73,87)(H,74,90)(H,75,88)(H,76,85)(H,77,93)(H,78,91)(H,79,86)(H,94,95)/t34-,35+,41+,42-,43+,44-,45+,46-,47-,48+,49-,52+/m0/s1
|
||||
| InChIKey |
VVEJUSYNERNRME-XGFVQVCISA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Somatostatin receptor 1 | Target Info | Agonist | [534701] | |
| Somatostatin receptor type 4 | Target Info | Agonist | [534701] | ||
| Somatostatin receptor type 2 | Target Info | Agonist | [534665] | ||
| Somatostatin receptor type 5 | Target Info | Agonist | [534665] | ||
| Somatostatin receptor type 3 | Target Info | Agonist | [533890] | ||
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interactionhsa04024:cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gastric acid secretionhsa04024:cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interactionhsa04080:Neuroactive ligand-receptor interaction | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| PathWhiz Pathway | Gastric Acid Production | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| GPCRs, Class A Rhodopsin-like | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signalingWP455:GPCRs, Class A Rhodopsin-like | |||||
| GPCR downstream signalingWP706:SIDS Susceptibility Pathways | |||||
| GPCR downstream signaling | |||||
| GPCRs, OtherWP455:GPCRs, Class A Rhodopsin-like | |||||
| References | |||||
| Ref 533890 | A human somatostatin receptor (SSTR3), located on chromosome 22, displays preferential affinity for somatostatin-14 like peptides. FEBS Lett. 1993 Apr 26;321(2-3):279-84. | ||||
| Ref 534665 | [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors. Eur J Pharmacol. 1998 May 8;348(2-3):311-20. | ||||
| Ref 534701 | Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10836-41. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.